GlassScriptPhysician profile
Deepak B Shah
NPI 1316993116
$8,668.70
in general payments reported to CMS, 2019-2025
36 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,234 · 2020: $512 · 2021: $1,399 · 2022: $1,086 · 2023: $783 · 2024: $951 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $77.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.13 |
| Education | $77.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,649.95 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $573.57 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $494.31 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $416.80 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $415.10 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $353.65 | 2020-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $338.56 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.65 | 2021-2025 | Jardiance |
| Amgen INC. | $329.92 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $313.32 | 2019-2024 | Xarelto, Invokana |
| Amarin Pharma, INC. | $307.09 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $296.12 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $250.98 | 2019-2021 | |
| Abbott Laboratories | $207.35 | 2019-2022 | |
| Biotronik INC. | $183.67 | 2019-2023 | Acticor 7 Vr-T Dx |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.